Management of hypertension in obstructive sleep apnea
- PMID: 36873802
- PMCID: PMC9976208
- DOI: 10.1016/j.ajpc.2023.100475
Management of hypertension in obstructive sleep apnea
Abstract
Obstructive sleep apnea (OSA) plays an important role in the development of hypertension. Thus, this review summarizes pharmacological and non-pharmacological approaches to blood pressure (BP) control in patients with OSA. Current treatments for OSA, such as continuous positive airway pressure, are effective at lowering BP. However, they only provide a modest BP reduction, and pharmacological treatment remains important for achieving optimal BP control. Furthermore, current guidelines for the treatment of hypertension do not make specific recommendations on pharmacological treatment protocols for controlling BP in patients with OSA. Moreover, the BP-lowering effects of various classes of antihypertensives may be different in hypertensive patients with OSA than in those without OSA due to the underlying mechanisms that promote hypertension in OSA. The acute and chronic increase in sympathetic nerve activity in patients with OSA explain the effectiveness of beta blockers in controlling BP in these patients. As activation of the renin-angiotensin-aldosterone system may also promote hypertension in OSA, angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers have generally been found effective for lowering BP in hypertensive patients with OSA. The aldosterone antagonist spironolactone also produces a good antihypertensive response in patients with OSA and resistant hypertension. However, there are limited data available that compare the effects of various classes of antihypertensive medication on BP control in those with OSA, and most data have been obtained from small-scale studies. This demonstrates the need for large-scale randomized controlled trials to evaluate a range of BP-lowering regimens in patients with OSA and hypertension.
Keywords: AHI, apnea hypopnea index; Antihypertensives; Apnea Hypopnea Index; BP, blood pressure; Blood pressure; CPAP, continuous positive airway pressure; Continuous positive airway pressure; Hypertension; MAD, mandibular advancement device; OSA, obstructive sleep apnea; Sleep apnea.
© 2023 The Authors.
Conflict of interest statement
None declared for all the authors.
Figures



Similar articles
-
Obstructive sleep apnea -related hypertension: a review of the literature and clinical management strategy.Hypertens Res. 2024 Nov;47(11):3085-3098. doi: 10.1038/s41440-024-01852-y. Epub 2024 Aug 29. Hypertens Res. 2024. PMID: 39210083 Free PMC article. Review.
-
Neuroendocrine and Inflammatory Responses to Losartan and Continuous Positive Airway Pressure in Patients with Hypertension and Obstructive Sleep Apnea. A Randomized Controlled Trial.Ann Am Thorac Soc. 2016 Nov;13(11):2002-2011. doi: 10.1513/AnnalsATS.201602-126OC. Ann Am Thorac Soc. 2016. PMID: 27548072 Clinical Trial.
-
Effects of CPAP on "vascular" risk factors in patients with obstructive sleep apnea and arterial hypertension.Vasc Health Risk Manag. 2013;9:229-35. doi: 10.2147/VHRM.S40231. Epub 2013 May 10. Vasc Health Risk Manag. 2013. PMID: 23690688 Free PMC article. Clinical Trial.
-
Continuous Positive Airway Pressure vs Mandibular Advancement Devices in the Treatment of Obstructive Sleep Apnea: An Updated Systematic Review and Meta-Analysis.Cureus. 2022 Jan 31;14(1):e21759. doi: 10.7759/cureus.21759. eCollection 2022 Jan. Cureus. 2022. PMID: 35251830 Free PMC article. Review.
-
Blood Pressure Response to Losartan and Continuous Positive Airway Pressure in Hypertension and Obstructive Sleep Apnea.Am J Respir Crit Care Med. 2016 Feb 1;193(3):310-20. doi: 10.1164/rccm.201505-0998OC. Am J Respir Crit Care Med. 2016. PMID: 26414380 Clinical Trial.
Cited by
-
2-Methoxyestradiol attenuates lung injury induced by chronic intermittent hypoxia via inhibiting the HIF1-α/SLC7A11 pathway.Sci Rep. 2025 May 21;15(1):17601. doi: 10.1038/s41598-025-02675-8. Sci Rep. 2025. PMID: 40399397 Free PMC article.
-
The Effects of Obstructive Sleep Apnea on the Cardiovascular System: A Comprehensive Review.J Clin Med. 2024 May 30;13(11):3223. doi: 10.3390/jcm13113223. J Clin Med. 2024. PMID: 38892933 Free PMC article. Review.
-
Renal interoception in health and disease.Auton Neurosci. 2024 Oct;255:103208. doi: 10.1016/j.autneu.2024.103208. Epub 2024 Jul 31. Auton Neurosci. 2024. PMID: 39128142 Review.
-
Effects of obstructive sleep apnea on nocturnal changes in blood pressure - a retrospective study.Hypertens Res. 2025 Apr;48(4):1379-1388. doi: 10.1038/s41440-024-02079-7. Epub 2025 Jan 27. Hypertens Res. 2025. PMID: 39871002
-
Symptom and comorbidity burden in hypertensive patients with obstructive sleep apnea.Front Endocrinol (Lausanne). 2024 Mar 4;15:1361466. doi: 10.3389/fendo.2024.1361466. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38501097 Free PMC article.
References
-
- Forouzanfar M.H., et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115mm Hg, 1990-2015. JAMA. 2017;317(2):165–182. - PubMed
-
- Williams B., et al. ESC/ESH guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of cardiology and the European society of hypertension. J Hypertens. 2018;36(10):1953–2041. - PubMed
-
- Ettehad D., et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957–967. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials